Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
2
조회
0
다운로드
18
인용
0
참고문헌
키워드
초록
The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word ‘fatty.’ Three pan-national liver associations set out to explore a new nomenclature to replace both NAFLD and its suggested alternative, metabolic (dysfunction)-associated fatty liver disease (MAFLD). They surveyed if a change in nomenclature and/or definition is favored and which nomenclature best communicates disease characteristics and increases awareness. In lieu of NAFLD/MAFLD, metabolic dysfunction-associated steatotic liver disease (MASLD) has been chosen, and an umbrella term, steatotic liver disease (SLD), encompassing the whole spectrum of liver disease, has been proposed. It has been suggested that cardiometabolic risk factors should be considered when categorizing SLD patients. Furthermore, a new subcategory, MASLD with increased alcohol intake (MetALD), casts light on a neglected group of patients with moderate or more alcohol consumption. The importance of metabolic dysfunction was acknowledged in this new nomenclature, but the precise contribution of metabolic dysfunction and alcohol consumption to the development and progression of SLD remains unclear. Herein, we review hepatologists’ and endocrinologists’ perspectives on the new nomenclature, along with its possible impact on clinical practice. Although it is premature to predict the settlement of the new nomenclature, this review may help build more evidence for a soft landing of it in the future.
Abstract
The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word ‘fatty.’ Three pan-national liver associations set out to explore a new nomenclature to replace both NAFLD and its suggested alternative, metabolic (dysfunction)-associated fatty liver disease (MAFLD). They surveyed if a change in nomenclature and/or definition is favored and which nomenclature best communicates disease characteristics and increases awareness. In lieu of NAFLD/MAFLD, metabolic dysfunction-associated steatotic liver disease (MASLD) has been chosen, and an umbrella term, steatotic liver disease (SLD), encompassing the whole spectrum of liver disease, has been proposed. It has been suggested that cardiometabolic risk factors should be considered when categorizing SLD patients. Furthermore, a new subcategory, MASLD with increased alcohol intake (MetALD), casts light on a neglected group of patients with moderate or more alcohol consumption. The importance of metabolic dysfunction was acknowledged in this new nomenclature, but the precise contribution of metabolic dysfunction and alcohol consumption to the development and progression of SLD remains unclear. Herein, we review hepatologists’ and endocrinologists’ perspectives on the new nomenclature, along with its possible impact on clinical practice. Although it is premature to predict the settlement of the new nomenclature, this review may help build more evidence for a soft landing of it in the future.
참고문헌 (56)
- Schaffner F, "Nonalcoholic fatty liver disease", Prog Liver Dis, 8, pp.283~298 (1986)
- Rinella ME, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease", Hepatology, 77, pp.1797~1835 (2023)
- European Association for the Study of the Liver(EASL), "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
- Francque SM, "Non-alcoholic fatty liver disease : A patient guideline", JHEP Rep, 3, pp.100322~ (2021)
- Ludwig J, "Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease", Mayo Clin Proc, 55, pp.434~438 (1980)
- Seul Ki Han, "Non-alcoholic fatty liver disease: Definition and subtypes", Clinical and Molecular Hepatology, 29, pp.5~16 (2023), 대한간학회
- Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
- Cameron Gofton, "MAFLD: How is it different from NAFLD?", Clinical and Molecular Hepatology, 29, pp.17~31 (2023), 대한간학회
- Ratziu V, "The times they are a-changin’(for NAFLD as well)", J Hepatol, 73, pp.1307~1309 (2020)
- Younossi ZM, "From NAFLD to MAFLD : Implications of a premature change in terminology", Hepatology, 73, pp.1194~1198 (2021)
- Seong Hee Kang, "From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?", Clinical and Molecular Hepatology, 27(2), pp.257~269 (2021), 대한간학회[DOI]
- Rinella ME, "A multi-society Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol (2023)[DOI]
- Rinella ME, "A multi-society Delphi consensus statement on new fatty liver disease nomenclature", Hepatology (2023)[DOI]
- Lazarus JV, "A global research priority agenda to advance public health responses to fatty liver disease", J Hepatol, 79, pp.618~634 (2023)
- Meijnikman AS, "Microbiome-derived ethanol in nonalcoholic fatty liver disease", Nat Med, 28, pp.2100~2106 (2022)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of alcohol-related liver disease", J Hepatol, 69, pp.154~181 (2018)
- 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
- Schneider KM, "A new era for steatotic liver disease : Evaluating the novel nomenclature in the UK Biobank", J Hepatol (2023)[DOI]
- Targher G, "Non-alcoholic fatty liver disease : a multisystem disease requiring a multidisciplinary and holistic approach", Lancet Gastroenterol Hepatol, 6, pp.578~588 (2021)
- Cleveland ER, "Low awareness of nonalcoholic fatty liver disease in a population-based cohort sample : the CARDIA study", J Gen Intern Med, 34, pp.2772~2778 (2019)
- Singh A, "Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort", Dig Dis Sci, 65, pp.978~986 (2020)
- Wieland AC, "Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk", J Clin Gastroenterol, 49, pp.e6~e10 (2015)
- Hardy T, "The European NAFLD Registry : A real-world longitudinal cohort study of nonalcoholic fatty liver disease", Contemp Clin Trials, 98, pp.106175~ (2020)
- Ayada I, "Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis : Focusing on the nonoverlap groups", Liver Int, 42, pp.277~287 (2022)
- Kuei-Chuan Lee, "Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis", Clinical and Molecular Hepatology, 29(1), pp.77~98 (2023), 대한간학회
- Lin S, "Comparison of MAFLD and NAFLD diagnostic criteria in real world", Liver Int, 40, pp.2082~2089 (2020)
- Kim D, "Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States", J Hepatol, 75, pp.1284~1291 (2021)
- Moon Joon Ho, "Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease", Gut and Liver, 16(3), pp.433~442 (2022), 거트앤리버 소화기연관학회협의회[DOI]
- Lee H, "Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk : A nationwide cohort study", Clin Gastroenterol Hepatol, 19, pp.2138~2147 (2021)
- Chang Y, "Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease : A cohort study", Hepatology, 69, pp.64~75 (2019)
- Simon TG, "Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease : A population-based cohort study", Hepatology, 74, pp.2410~2423 (2021)
- Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
- Zheng M, "Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study", JHEP Rep, 5, pp.100692~ (2023)
- Vilarinho S, "Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD", Hepatology, 74, pp.2241~2250 (2021)
- Hagström H, "Administrative coding in electronic health care recordbased research of NAFLD : An expert panel consensus statement", Hepatology, 74, pp.474~482 (2021)
- Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies", Nat Med, 24, pp.908~922 (2018)
- Sanyal AJ, "Mechanisms of disease : pathogenesis of nonalcoholic fatty liver disease", Nat Clin Pract Gastroenterol Hepatol, 2, pp.46~53 (2005)
- Alberti KG, "Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
- Carr DB, "Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome", Diabetes, 53, pp.2087~2094 (2004)
- Zelber-Sagi S, "Nutrition and physical activity in NAFLD : an overview of the epidemiological evidence", World J Gastroenterol, 17, pp.3377~3389 (2011)
- Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
- Younossi ZM, "Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
- Ratziu V, "Elafibranor, an agonist of the peroxisome proliferatoractivated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening", Gastroenterology, 150, pp.1147~1159 (2016)
- Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : Results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
- Ratziu V, "Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis : Final analysis of the phase 2b CENTAUR study", Hepatology, 72, pp.892~905 (2020)
- Moon JS, "SGLT2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease", Trends Endocrinol Metab, 33, pp.424~442 (2022)
- Zhou P, "Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis", Front Endocrinol(Lausanne), 14, pp.1144838~ (2023)
- Armstrong MJ, "Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis(LEAN) : a multicentre, doubleblind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
- Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
- Ghosal S, "A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist(GLP1-RA)in nonalcoholic fatty liver disease(NAFLD)with type 2 diabetes(T2D)", Sci Rep, 11, pp.22063~ (2021)
- Wong C, "Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: A meta-analysis", Front Endocrinol(Lausanne), 12, pp.609110~ (2021)
- Åberg F, "Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population", Hepatology, 67, pp.2141~2149 (2018)
- Ekstedt M, "Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease", Scand J Gastroenterol, 44, pp.366~374 (2009)
- Dunn W, "Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease(NAFLD)", J Hepatol, 57, pp.384~391 (2012)
- Kwon HK, "Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease", Liver Int, 34, pp.129~135 (2014)
- You M, "Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein(SREBP)", J Biol Chem, 277, pp.29342~29347 (2002)